Hunter syndrome is a very rare, life threatening genetic condition that affects mostly males and results from the absence or deficiency of the lysosomal enzyme iduronate-2-sulfatase.
Without this enzyme, cellular waste products accumulate in tissues and organs, which then begin to malfunction.
Life expectancy for people with the severe form of the disease is commonly 10 to 20 years.
Expected early in 2007, the EU Marketing Authorisation will result in a unified labelling that will be valid in the current EU 25 member states as well as in Iceland and Norway.
Earlier this year, ELAPRASE has been approved by the USFDA for Hunter syndrome.
Source: Shire plc
Comment Preview